Prescriptions & Primetime: Medical and Pharma Advertisers Spend Billions on TV
In Q1 2023, despite a nearly 1,900% increase in healthcare and pharma digital ad spending since 2011, nearly 190 medical and pharmaceutical companies—including industry leaders AbbVie, GSK, and Pfizer—collectively spent over $2 billion on broadcast and cable TV advertising, marking a 13% increase from Q1 2022, with significant boosts driven by promotions for dietary supplements, HIV/AIDS prescriptions, and AbbVie's arthritis drug Rinvoq amid Humira patent losses and biosimilar competition.
The rapid ascent of digital advertising has made us immune to what should be head-turning statistics. Between 2011 and 2024, healthcare and pharma digital ad spending is expected to increase by approximately 1,900%.
That increase paints a vivid picture: healthcare advertisers are finally embracing digital channels after years of shunning them for traditional ones.
But medical and pharma advertisers still aren’t saying goodbye entirely to their long-time partners in traditional advertising. In Q1 2023, almost 190 medical & pharmaceutical companies spent more than $2 billion on broadcast and cable TV, up by 13% from Q1 2022.
Industry Titans Drive Ad Spending in Q1
The healthcare and pharma industries have always been dominated by a handful of titans, with companies such as Pfizer, AbbVie, and GlaxoSmithKline (GSK) among the most prominent. Unsurprisingly, these titans also have a significant presence in broadcast and cable TV advertising.
In Q1, AbbVie (up by 42%), GSK (up by ~80%), and Pfizer (up by 66%) all increased their investment in broadcast and cable TV, collectively spending more than $588 million. Overall, they accounted for 28% of the broadcast and cable TV investment from medical & pharmaceutical advertisers in the first quarter.
While spending was steady throughout the quarter—each month saw investments between $663 million and $738 million—January saw the biggest increase when approximately 170 advertisers collectively increased spending by 21% year-over-year to $738 million.
Much of that increase came from advertisers promoting dietary supplements and HIV/AIDs prescriptions, but also from those at AbbVie who boosted their budget by more than 1,000% to promote their arthritis medication, Rinvoq.
The increase to promote Rinvoq comes as the company loses patent protection of their best-selling drug Humira, and at least eight biosimilars (nearly identical versions of the drug) hit the market in 2023, including Amjevita (Amgen), Cyltezo (Boehringer Ingelheim), and Hyrimoz (Sandoz).
Given the company’s historical reliance on Humira—AbbVie generated 37% of its revenue in 2021 from global sales of Humira—advertisers will dig deep this year to make up for the level playing field. That’ll mean more dollars to promote Rinvoq but also increased investments to drive sales of medications for other treatments, including psoriasis (Skyrizi), schizophrenia (Vraylar), and dry eye (Restasis).
Broadcast TV Advertising Falls As Viewership Declines
Not long ago, the trio of three-letter broadcast networks—ABC, NBC, and CBS—had a complete stranglehold on ad budgets.
Declining viewership in broadcast TV, however, is loosening their grip. In Q1, medical & pharma advertisers decreased spending on broadcast TV by 1% following a year in which all major networks saw a drop in viewers by at least 6%.
That said, two networks—CBS and Fox—did see spending rise. For CBS, the increase comes following its 15th consecutive year as the most-watched network. Through May 14, CBS was averaging almost 6 million primetime viewers a night. And as of April 30, the network generated about 827 billion viewing minutes across its network, Paramount+, Pluto TV, and the CBS app, up by 2.2% from last year and 330 billion more viewing minutes than its closest broadcast competitor.
Overall, spending from medical & pharma on CBS increased by 23%, with top drivers coming from advertisers promoting psoriasis prescriptions. Advertisers for Pfizer and Sanofi also increased their investment, with the latter doing so by 90% year-over-year to promote Dupixent (asthma).
At the same time, advertisers, including those at AbbVie, Bristol-Myers Squibb Company, and Pfizer increased their investment in Fox by 120% year-over-year, but much of that can be attributed to the Super Bowl.
As spending on broadcast TV fell, spending on cable TV jumped by 27% to over $1.2 billion, thanks to big investments from companies like Merck & Co., Inc. (Gardasil, Keytruda, etc.), which increased its investment by over 100%. United We Stand also increased its investment by 53% year-over-year to promote Balance of Nature (dietary supplement).
Other companies that increased their investment in cable TV advertising include Merck & Co., GSK, and Johnson & Johnson.
Broadcast Networks Pivot into the Streaming Wars
A drop in ad revenue is never a good thing, and the broadcast networks are undoubtedly looking for ways to woo advertisers back. It would be far worse, however, if they were just sitting idly by as revenue declined.
They’re not.
Each of these major networks has a hand in the streaming wars, which have serious advertising implications.
Consider Peacock. The NBC-owned streaming service has more than 22 million paid subscribers as of Q1 2023, up from 13 million in Q1 2022.
That growth has spurred advertising innovation. Last year at NewFronts, Peacock launched two new ad formats “to make marketers the star of the show with in-scene ads.”
At NewFronts this year, NBC announced something even grander: Integrating Peacock into its greater entertainment ecosystem.
According to Jenny Burke, EVP of Advertising Strategy at NBCUniversal, “We are bringing the power of One Platform, which is the entire content and technology platform of NBC Universal, and supercharging those efforts cross-platform and then within Peacock.”
A big part of this innovation is Spotlight+, a full-brand takeover designed to reach viewers wherever they’re watching, whether that’s on Peacock or on primetime TV. According to Collette Winn, VP of Strategy and Operations for Creative Partnerships at NBCUniversal, Spotlight+ gives brands “total ownership of the day.”
The broadcast titan previously announced Must ShopTV to let consumers shop for products appearing in the content as they evolve their strategy to appeal to retailers and DTC brands.
Advertising innovation isn’t siloed to NBC, either. Hulu, which is owned by The Walt Disney Company (owned by ABC), drove more than $3 billion in ad revenue in 2022.
So, while it’s clear broadcast networks are losing ground to their counterparts in cable, they’re making up for it elsewhere, and advertisers will continue to take notice.
Related
Firearms & Accessories Advertising On the Rise in the US
In the first half of 2022, firearms and accessories advertisers in the US increased their spending by 21% year-over-year to over $67 million, with significant investments not only in promoting guns but also in body armor, driven by rising demand, safety concerns, and increased police funding despite ongoing calls for gun reform.
22 Categories to Watch in ‘22: Top Travel Advertising Trends
As pandemic restrictions eased in 2021, the travel industry saw a surge in "revenge travel" driven by vaccinated families eager to make up for lost experiences, with leisure travel rebounding strongly while business travel lagged, prompting airlines to adjust loyalty programs, though ongoing COVID-19 risks like the Omicron variant continue to create uncertainty despite significant advertising investments by top travel companies targeting shifting consumer behaviors.
From Signal to Strategy: Navigating What's Next in Media Investment
In 2025, U.S. media investment plateaued at $281 billion with digital media dominating 65% of spend, prompting advertisers to shift from broad, scale-driven omnichannel strategies to precision-focused, outcome-led investments that prioritize high-engagement formats like social (+9.9%) while reducing spend in declining areas such as mobile apps (−3.4%), reflecting a disciplined approach centered on measurable returns amid fragmented consumer attention.
2023 MediaRadar Prediction: Gambling Advertisers Bet Big on Traditional Formats
In 2022, gambling advertisers, led by companies like DraftKings and FanDuel, increased their spending by 22% to over $738 million—primarily investing 69% in traditional media such as national broadcast and cable TV (notably CBS and NBC) and print ads—reflecting a strategic focus on established formats despite the younger demographic and growth of betting apps, with TV ad spending alone rising 27% year-over-year.
2023 MediaRadar Prediction: Beauty Advertisers Take Advantage of the Lipstick Effect
The 2023 MediaRadar report highlights that despite mixed signals like a 10% drop in Estée Lauder’s makeup sales, beauty advertisers capitalized on the "lipstick effect" during economic downturns—evidenced by a 48% surge in lipstick sales in Q1 2022—and overall beauty ad spending rose 13% to $4.6 billion through October 2022, with top categories including anti-aging skincare, cosmetics, deodorant, haircare, and skincare, which is projected to grow to a $145 billion market by 2028, indicating continued robust advertising investment into 2023.
MediaRadar's Advertising Predictions for 2023
MediaRadar's 2023 advertising predictions highlight how rising interest rates, economic challenges, and media industry consolidations—such as potential sales and mergers among streaming services like Hulu and Discovery+—will create both disruptions and opportunities for advertisers to capitalize on lower-priced ad inventory amid ongoing market turmoil.